ERS Genomics Announces Agreement With Applied StemCell To Commercialize CRISPR Gene Editing Solutions

Product News

Published: September 21, 2020

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "ERS Genomics Announces Agreement With Applied StemCell To Commercialize CRISPR Gene Editing Solutions"

First Name*

Last Name*

Email Address*

Country*

Company Type*

Job Function*

Would you like to receive further email communication from Technology Networks?

Listen with

Speechify

0:00

Thank you. Listen to this article using the player above. ✖

Read time:

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr Emmanuelle Charpentier, announced on the 15th September that it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents and genetically modified cell lines and organisms.

Applied StemCell is a fast growing California based biotech company with a goal of advancing gene editing and stem cell innovation worldwide. Applied StemCell offers a wide variety of preclinical research services including cell and animal model generation, antibody discovery, and preclinical assay services to support cell/gene product development.

Eric Rhodes, CEO of ERS Genomics stated: “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."

Ruby Tsai, CEO of Applied StemCell added: “We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,”

Financial details of the agreement are not disclosed.